DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Active, not recruiting · Phase 1 · NCT04042701
Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
At a glance
- Research payments reported, 2025
- $400,271
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 115
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca, Merck Sharp & Dohme LLC)
- Tested
- Trastuzumab deruxtecan (DS-8201a) (drug), Trastuzumab deruxtecan (DS-8201a) (drug), Pembrolizumab (drug)
- Dates
- Started 2020-02-10; completion 2027-03-31
- Results posted
- Not yet
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
From ClinicalTrials.gov, last updated 2025-11-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $400,271 in research payments for this study in 2025 (54 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jonathan S. Chien, M.D. Internal Medicine · Montebello, CA
- Hope S. Rugo, MD Hematology · San Francisco, CA
- Aixa Soyano Muller, MD Hematology & Oncology · Tampa, FL
- Hema M. Vankayala, MD Hematology & Oncology · Fleming Island, FL
- Ralph V. Boccia, M.D. Hematology & Oncology · Bethesda, MD
- Hossein Borghaei, M.D. Magnetic Resonance Imaging (MRI) · Philadelphia, PA
- Robert Droder, M.D. Hematology & Oncology · Tyler, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cancer Specialists Llc $105,609
- American Oncology PArtners of Maryland PA $91,740
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $78,683
- Ascension St Vincent's Riverside, FL $75,486
- Moffitt Cancer Center $30,305
- The Institute for Cancer Research $15,949
- University of Texas Health Science Center at Tyler, TX $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.